跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
TGA
/
ABEVMY bevacizumab 100 mg/4 mL concentrate injection for solution vial
Approved
STANDARD
ABEVMY bevacizumab 100 mg/4 mL concentrate injection for solution vial
Maxx Pharma Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
fd1b318b8d4f9f0b
Company
Maxx Pharma Pty Ltd
Type
Standard
Approval Details
Approval Id
fd1b318b8d4f9f0b
Product Name
ABEVMY bevacizumab 100 mg/4 mL concentrate injection for solution vial
Artg Id
334816
Artg Name
ABEVMY bevacizumab 100 mg/4 mL concentrate injection for solution vial
Sponsor
Maxx Pharma Pty Ltd
Company Detail Path
/organization/maxx-pharma-pty-ltd
Artg Date
2021-09-06
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Consumer Medicine Info
https://medical-cdn.nocode.com/drug_tga/957c2c2864cbbe46ddc45aebb71d2f23.pdf
Product Information
https://medical-cdn.nocode.com/drug_tga/e4c5fc4260647cc22c3dc5de567f6dd5.pdf
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
fd1b318b8d4f9f0b
Type
Standard
Back to TGA Approvals
ABEVMY bevacizumab 100 mg/4 mL concentrate injection for solution vial - TGA Drug Approval Details
